文献速递药物不良反应与药物警戒

PEG化药物是否与超敏反应相关?意大利自发药物不良反应报告系统分析

Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System.
PubMed 文献 · Drug Saf · 2023-02-15

基于意大利自发药物不良反应报告系统数据库,比较PEG化药物与非PEG化对照药物的超敏反应报告情况。PEG化药物超敏反应报告频率更高(11.7% vs 9.4%,p < 0.0001),报告率比值从1.4至20.0不等,中位起病时间更短(10天 vs 36天),提示PEG化可能触发药物相关超敏反应。

要点

  • PEG化药物超敏反应报告频率高于非PEG化对照药(11.7% vs 9.4%)。
  • PEG化药物超敏反应中位起病时间10天,短于非PEG化对照药的36天。
  • 以全部其他药物为参照时未观察到超敏反应报告不成比例,可能存在掩蔽效应。

核心结论

  • 意大利自发不良反应数据库分析提示PEG化可能参与触发药物相关超敏反应,尤其是临床相关反应。
  • 但以全部其他药物为参照时,PEG化与非PEG化药物均未观察到超敏反应报告不成比例,可能存在掩蔽效应。

研究设计与样本

  • 研究基于意大利自发药物不良反应报告系统数据库,选取PEG化活性物质和/或PEG化脂质体药物的不良反应报告,并提取含相同非PEG化活性物质和/或非PEG化脂质体(或同机制类别化合物)的报告作为对照。
  • 共纳入PEG化药物相关不良反应报告3865份,非PEG化对照药报告11961份;约三分之二患者为女性,报告多涉及46至64岁患者。

主要发现

  • PEG化药物超敏反应报告频率高于非PEG化对照药(11.7% vs 9.4%,p < 0.0001)。
  • PEG化药物超敏反应报告率高于非PEG化对照药,报告率比值范围从培非格司亭对比非格司亭的1.4(95%CI 0.8-2.5)到聚乙二醇干扰素α-2a对比干扰素α-2a的20.0(95%CI 2.8-143.5)。
  • PEG化药物超敏反应中位起病时间为10天(四分位距0-61),非PEG化对照药为36天(四分位距3-216)。
  • 比较PEG化与非PEG化药物超敏反应报告的报告比值比为1.3(95%CI 1.1-1.4),差异有统计学意义。
  • 以全部其他药物为参照时,PEG化与非PEG化药物均未显示超敏反应报告不成比例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Evidence highlights the allergenic potential of PEGylated drugs because of the production of anti-polyethylene glycol immunoglobulins. We investigated the risk of hypersensitivity reactions of PEGylated drugs using the Italian spontaneous adverse drug reaction reporting system database. METHODS: We selected adverse drug reaction reports attributed to medicinal products containing PEGylated active substances and/or PEGylated liposomes from the Italian Spontaneous Reporting System in the period between its inception and March 2021. As comparators, we extracted adverse drug reaction reports of medicinal products containing the same non-PEGylated active substances and/or non-PEGylated liposomes (or compounds belonging to the same mechanistic class). A descriptive analysis of reports of hypersensitivity reactions was performed. Reporting rates and time to onset of hypersensitivity reactions were also calculated in the period between January 2009 and March 2021. As a measure of disproportionality, we calculated the reporting odds ratio. RESULTS: Overall, 3865 adverse drug reaction reports were related to PEGylated medicinal products and 11,961 to their non-PEGylated comparators. Around two-thirds of patients were female and reports mostly concerned patients aged between 46 and 64 years. The frequency of hypersensitivity reactions reporting was higher among PEGylated versus non-PEGylated medicinal products (11.7% vs 9.4%, p < 0.0001). The hypersensitivity reaction reporting rates were higher for PEGylated medicinal products versus non-PEGylated medicinal products, with reporting rate ratios that ranged from 1.4 (95% confidence interval 0.8-2.5) for pegfilgrastim versus filgrastim to 20.0 (95% confidence interval 2.8-143.5) for peginterferon alpha-2a versus interferon alpha-2a. The median time to onset of hypersensitivity reactions was 10 days (interquartile range: 0-61) for PEGylated medicinal products, and 36 days (interquartile range: 3-216) for non-PEGylated comparators. Statistically significant reporting odds ratios were observed when comparing the reporting of hypersensitivity reactions for PEGylated versus non-PEGylated medicinal products (reporting odds ratio: 1.3; 95% confidence interval 1.1-1.4). However, when using all other drugs as comparators, the disproportionality analysis showed no association with hypersensitivity reactions for PEGylated nor non-PEGylated medicinal products, thus suggesting that many other triggers of drug-induced hypersensitivity reactions play a major role. CONCLUSIONS: The findings of this analysis of the Italian spontaneous adverse drug reaction database suggest a potential involvement for PEGylation in triggering drug-related hypersensitivity reactions, especially clinically relevant reactions. However, when comparing both PEGylated and non-PEGylated drugs under study to all other drugs no disproportionate reporting of hypersensitivity reactions was observed, probably due to a masking effect owing to the presence in the same database of other medicinal products increasing the threshold required to highlight a safety signal when the entire database is used as a reference.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Crisafulli S, Cutroneo PM, Luxi N, et al. Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System. Drug Saf. 2023. PMID: 36790561. doi:10.1007/s40264-023-01277-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。